Table 3 Standardized association between intensive therapy and primary outcome, nonrenal CVD, and MACE stratified by baseline BP levels

	Baseline BP subgroup	No. of events			Model 1				Model 2				Model 3
	Baseline BP subgroup	Total	Intensive therapy	Standard therapy	HR	95% CI	P value	P for interaction	HR	95% CI	P value	P for interaction	HR	95% CI	P value	P for interaction
Primary outcome	BP ≥ 130/80 mmHg	218/3335	91/1638	127/1697	0.73	0.56–0.96	0.022	0.026	0.69	0.52–0.91	0.009	0.026	0.70	0.52–0.93	0.015	0.027
Primary outcome	BP < 130/80 mmHg	63/1645	37/845	26/800	1.39	0.84–2.30	0.19	0.026	1.34	0.80–2.25	0.26	0.026	1.56	0.91–2.65	0.10	0.027
Nonrenal CVD	BP ≥ 130/80 mmHg	143/3335	56/1638	87/1697	0.66	0.47–0.92	0.014	0.078	0.64	0.45–0.91	0.013	0.069	0.67	0.47–0.95	0.025	0.070
Nonrenal CVD	BP < 130/80 mmHg	45/1645	25/845	20/800	1.21	0.67–2.17	0.53	0.078	1.22	0.66–2.23	0.53	0.069	1.28	0.68–2.39	0.45	0.070
MACE	BP ≥ 130/80 mmHg	102/3335	39/1638	63/1697	0.63	0.43–0.95	0.026	0.014	0.65	0.43–0.99	0.046	0.021	0.67	0.44–1.02	0.064	0.017
MACE	BP < 130/80 mmHg	36/1645	23/845	13/800	1.70	0.86–3.36	0.12	0.014	1.73	0.85–3.51	0.13	0.021	1.83	0.87–3.83	0.11	0.017

Model 1 was adjusted for sex and age. Model 2 was adjusted for sex, age, body mass index, smoking, hypertension, heart rate, duration of diabetes, diabetic neuropathy, diabetic nephropathy, hemoglobin A1c, low-density lipoprotein cholesterol, and estimated glomerular filtration rate. Model 3 was adjusted for all confounders in model 2, prescribed antihypertensive drugs, antiplatelet drugs, standard statins, and strong statins
CVD cardiovascular diseases, MACE major adverse cardiovascular events, BP blood pressure, HR hazard ratio, CI confidence interval

Quick links

Search